NBY Stock Overview
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NovaBay Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.081 |
| 52 Week High | US$1.28 |
| 52 Week Low | US$0.065 |
| Beta | 2.01 |
| 1 Month Change | -22.83% |
| 3 Month Change | -52.91% |
| 1 Year Change | -92.79% |
| 3 Year Change | -99.71% |
| 5 Year Change | -99.69% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| NBY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.9% | 1.0% | -0.7% |
| 1Y | -92.8% | 11.6% | 22.3% |
Return vs Industry: NBY underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: NBY underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| NBY volatility | |
|---|---|
| NBY Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NBY's share price has been volatile over the past 3 months.
Volatility Over Time: NBY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25 | Justin Hall | novabay.com |
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
NovaBay Pharmaceuticals, Inc. Fundamentals Summary
| NBY fundamental statistics | |
|---|---|
| Market cap | US$2.91m |
| Earnings (TTM) | -US$16.70m |
| Revenue (TTM) | US$14.73m |
0.2x
P/S Ratio-0.2x
P/E RatioIs NBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBY income statement (TTM) | |
|---|---|
| Revenue | US$14.73m |
| Cost of Revenue | US$6.83m |
| Gross Profit | US$7.90m |
| Other Expenses | US$24.59m |
| Earnings | -US$16.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 53.61% |
| Net Profit Margin | -113.38% |
| Debt/Equity Ratio | 34.3% |
How did NBY perform over the long term?
See historical performance and comparison